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The invasive tumor size measurement by microCT was underestimated in 24 cases. (33%), overestimated in 37 cases. (51%), and matched it exactly in 11 cases. (15%) compared to the histopathology measurement for all the cases. However, microCT Tstage classification differed from histopathology in only 11. (15.2%) with 6 cases. (8.3%) classified as a higher stage by microCT, and 5 cases. (6.9%) classified as lower compared to histopathology. In addition, microCT demonstrated a statically significant strong agreement (κ =0.6, P < 0.05) with pathological tumor size and staging for invasive ductal 
INTRODUCTION
Tumor size is a major determinant for staging and predicting the outcome for cancer patients. [1] According to the American Joint Committee on Cancer TNM staging system for breast cancer, the invasive primary tumor size classifies the breast cancer pathologically into five groups. T0 for tumors that are undetectable grossly, T1 for tumors measured ≤2 cm, T2 for tumors measured >2 cm -5 cm, T3 for those measured >5 cm, and T4 for tumors of any size with infiltration either to the skin or chest wall.
[2] Because of this staging system, it is important to report an accurate measurement of primary tumor size since 1 mm variation in the measurement can lead to a change in Tstage classification, which in turn will alter the patient's treatment options. [3] Although the pathology is the gold standard for measuring and staging the tumor size, there are certain factors that could affect the accuracy of tumor measurement. [3] These include fixation of the tissue in the formalin, which might cause tissue expansion or shrinkage, as well as the histological type and growth pattern of the tumor. [3] For example, invasive ductal carcinoma (IDC), which is the most common type of breast cancer, can be measured easily during gross examination because it forms a mass that has circumscribed irregular borders. On the other hand, invasive lobular carcinoma (ILC), which accounts for only 5-10% of all breast cancers, tends to grow in a diffuse pattern, without forming a mass. [4] Because of this, measuring and staging the ILC grossly is challenging. Another situation that could potentially comprise the measurement and staging of the tumor occurs when the pathological assessment is not available, or cannot be performed due to shortage of laboratory materials. To deal with this, breast imaging modalities such as breast ultrasound, mammography, and magnetic resonance imaging are used to stage the tumor clinically and inform treatment options for the patients. [5] However, previous studies have shown none of these modalities are accepted as the standard for tumor size measurement. [6, 7, 8, 9, 10, 11, 12, 13, 14] Microcomputed tomography (microCT) is a noninvasive Xray technology that provides highresolution (10 mm) threedimensional (3D) images of ex vivo specimens. [15] With this method, it is possible to visualize and obtain the 3D measurements of the invasive tumor without cutting the tumor, as is the case in the pathological procedure. Few studies have used microCT technology to evaluate the interior structure of breast tissue. [16, 17] These studies demonstrated that microCT is capable of identifying the different components of breast tissue, as well as differentiating between benign and malignant breast tumor. However, none of these studies measured the malignant tumor size because they were performed on breast core biopsy specimens, which contain only a small section of the lesion and may not be representative of a breast lesion. Since none of the modalities that described above were shown to perform adequate tumor measurement, a new modality is needed. microCT may help to confirm the final pathological tumor size measurement in cases where the invasive tumor size could be larger or smaller than gross examination would demonstrate. Therefore, microCT can serve as a clinical decision support system for measurement and staging of invasive breast cancers.
The first objective of this study was to evaluate the accuracy of microCT in measuring the tumor size in breast lumpectomy specimens and to determine whether there is a change in Tstage when the microCT tumor size was different from the pathological tumor size in both invasive ductal and lobular carcinoma. The second objective was to assess the sensitivity and specificity of microCT in detecting the malignant tumor size ≤2 cm.
MATERIALS AND METHODS
This study was approved by the Massachusetts General Hospital (MGH) institutional review board. The study was conducted in two periods, the first period was from June 2011 to September 2011, and the second period was from August 2013 to December 2013. Specimens from women with a confirmed diagnosis of breast cancer by biopsy, and who were scheduled to have breast lumpectomy surgery for the first time during the aforementioned periods were scanned. Only those who were diagnosed with invasive breast cancer were included in this study. Those who were diagnosed with noninvasive breast disease such as benign lesions, or in situ disease and those who were scheduled to have breast reexcision surgery were excluded from the study. All the participants were consented prior to their participation in the study before or on the day of the surgery.
MicroComputed Tomography Measurements
Once the malignant tumors were excised from the patients, they were scanned by one of two machines: A tabletop microCT SkyScan 1173 (Bruker Corporation, SkyScan, Belgium), which was used to scan the first 50 invasive cancer specimens, or a microCT Nikon XT H 225 system (Nikon, Japan) which scanned the rest of the specimens. Both machines were calibrated in the early morning on the day of the surgery. In addition, the both machines have the similar structural and functional proprieties. They are composed of an Xray microfocus tube that has a voltage range of 40-130 kV, and power of 8 W as Xray sources, a rotatory movable stage, and a detector. Each specimen was placed inside a transparent container before being placed on the rotary stage, where it was rotated 360° and scanned at 0.40-0.80° incremental rotation steps. Each scan lasted no longer than 15 min. Some specimens had a localized needle wire, which was removed gently before scanning the specimens to avoid the image artifacts. The excised specimens were delivered to the pathology grossing laboratory after the scan was completed, where they were processed via the standard pathological protocol.
Dedicated microCT technicians assembled a 3D image representation of the specimen from the raw scan data using SkyScan's NRecon and VideoGraphics Laboratory (VGL) studio programs. The reconstructed images were analyzed using the following software: Data viewer, CTVox, and VGL studio [ Figure 1 ].
The images were previewed from three orthogonal perspectives: From the Xrays source, from the micro CT window on the right side, and from the top down. Before the linear measurement was obtained, the measurement tool was calibrated by centimeters.
The microCT measurements were performed by an independent physician who was blinded to the pathology results and the medical records. The physician was also trained to read the microCT images. The single linear measurement of the largest diameter of the tumor was recorded after identifying the tumor edges in the microCT image.
Pathological Measurements
The specimens were processed following routine pathology procedures by the pathologist or pathologist assistant. The excised specimens were inked on the surface with one color if the surgeon provided no further orientation. If the specimens were oriented, an inking protocol with four colors was used in the gross examination. The specimens were serially sectioned in a fresh state, and the gross examination findings were recorded as a part of the routine pathology report, which included size and characteristics of the grossly recognized mass, distance to the inked margins, and findings in the surrounding breast parenchyma. Additional findings such as needle orientation wires or radiographic clips were also recorded.
In most cases, representative sections of the tumor with closest margins were formalinfixed and paraffin embedded by routine histopathological processing procedures. In some cases without grossly recognizable masses, the breast excision specimen was entirely submitted. 5 um sections were cut and stained with Hematoxylin and Eosin, and microscopically evaluated by the pathologist.[2, 18, 19] Tumor size measurements were based on either the gross or microscopic examinations or a combination of these. The cases were evaluated and reported by breast pathologists. Information from the pathology reports was subsequently extracted for this study.
Statistical Data Analysis
For descriptive analysis of the sample features, mean, standard deviation (SD), and percentage were calculated.
For the outcome measures, the percentages of the microCT cases that yielded a larger, smaller, or equal size compare to the pathology report were calculated. The match cases were defined as the microCT tumor size cases that matched to the pathological tumor size cases to the first decimal place. In addition, the percentage of changes in Tstage was assessed when microCT tumor size measurement was different from the pathology.
The study subjects were categorized into two groups based on invasive tumor maximum dimension in the TNM classification staging system. Group 1 contained subjects with tumor maximum dimension ≤2 cm, which is referred to as stage T1. Group 2 contained subjects with tumor maximum dimension >2 cm, which is referred to as stage T2.
Validity measurements such as sensitivity and specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated with 95% confidence intervals (CIs). Group 1 with tumor size ≤2 cm was treated as the positive result. The reason behind this was to evaluate the ability of microCT to detect the tumor size with the maximum dimension of ≤2 cm in across.
Cohen's Kappa was calculated with 95% CIs to measure the agreement between microCT and pathology.
To assess the agreement graphically between the microCT and pathology in measuring the maximum dimension of the invasive tumor, an AltmanBland plot with 95% limit of agreement was generated.
P ≤ 0.05 were considered statistically significant. All the study analyses were carried out using R version 3.0.3. [20] RESULTS 72 female subjects who were diagnosed with primary invasive breast cancer and subsequently underwent breast lumpectomy were examined in detail in this study. Among 72 lesions, 65 cases (90.3%) were IDC, and 7 cases (9.7%) were ILC. 8 out of 65 cases (12%) of IDC did not have in situ disease. The final diagnosis of ILC cases was confirmed by having negative Ecadherin stain [ Table 1 ].
The mean diameter and SD via microCT measurement was 1.40 cm (±0.73), with measurement was ranging from 0.2 to 3.8 cm, while the mean diameter and SD by pathological measurement was 1.36 cm (±0.73), with measurement was ranging from 0.15 to 3.5 cm for IDC. For the ILC, the mean diameter and SD via microCT measurement was 1.90 cm, with measurement was ranging from 1.1 to 2.9 cm, while the mean diameter and SD by pathological measurement was 1.35 cm, with measurement was ranging from 0.25 to 2.1 cm. Table 2 shows that the microCT measurement yielded a slightly smaller size than pathology tumor size measurement in 32% of cases, yielded a larger size in 51% of cases, and an equivalent size in 17% of cases for IDC. For the ILC, the microCT measurement yielded a slightly smaller size than the pathology tumor size measurement in 43% of cases, yielded a larger size in 57% of cases, and equivalence in none of the cases. Overall, microCT measurement yielded a slightly smaller size than pathology tumor size https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687161/?report=printable 5/13 measurement in 24 cases (33%), yielded a larger size in 37 cases (51%), and an equivalent size in 11 cases (15%) for all breast cancer cases. Table 4 shows that the Kappa statistic demonstrated statistically significant agreement between the micro CT and pathology for tumor size measurement and Tstage classification for IDC (κ =0.6) and no agreement for ILC (κ = −0.2) However, ILC agreement result was not statistically significant.
The Altman bland plots in [ Figures 2 and 3] showed that the 95% limit of agreement between microCT and pathology measurements was -0.8 to 1 cm for IDC, and −1.6 to 2.9 cm for ILC. The solid line represents the mean difference between the two measurements, and the dashed line represents the upper and lower 95% limit of agreement.
DISCUSSION
In this study, we examined the agreement between microCT and pathology measurements of the breast malignant tumor size in 72 subjects who had a confirmed diagnosis of primary breast cancer by histopathology. [21, 22] To our best knowledge, we are the first to report the use of microCT in assessing the breast malignant tumor size of lumpectomy specimens. Our study demonstrated that microCT yields a slightly larger size than the pathological invasive tumor size in 37 cases out of 72 cases (51%). We would assume that the Tstage of the overestimated cases by microCT would be changed into lower stage after comparing to pathology. However, we found that Tstage changed into lower stage only in 5 out of 11 (6.9%) cases in which microCT and pathology yielded a different Tstage classification. In addition, a similar result was observed in 24 cases (33%) that were underestimated by the microCT, where only 6 cases out of 11 (8.3%) changed into a higher stage. This could be explained by our finding that the difference between the microCT and the pathology measurements were within the value range of each stage, which could be considered as a clinically insignificant.
The over/underestimation of invasive tumor size by microCT could be explained by tissue fixation in formalin and tissue processing. These factors could change the microscopic tumor size measurement by causing tissue expansion and shrinkage. [3] These effects can occur at any stages of the specimen processing from receiving the specimen in fixative solution to embedding the tissue in the paraffin blocks. One study reported a reduction of the tumor size measurement between the fresh specimens and the final processed specimens in 40% of 50 breast cancer cases, with a mean difference of 2.4 mm from the fresh specimen measurement, and increased of measured tumor size in 18% of the 50 cases with a mean difference of 1.7 mm. [23] In our study, we were unable to eliminate this effect completely in 15 cases where the tumor size was measured only by the microscope. However, for the rest of the cases, all the specimens were cut in the fresh state and measured during gross examination.
Additional explanations for the overestimation of tumor size could be due to other factors related to the lumpectomy procedure. The procedure can cause local bleeding and edema. Moreover, a previous core biopsy may cause an inflammatory reaction and fibrosis that could result in tumor size overestimation by microCT. [24, 25] This study also demonstrated a statistically significant substantial agreement for measuring and staging IDC tumors. However, there was no agreement for measuring and staging ILC tumors. Moreover, the ILC tumors exhibited the lowest sensitivity (67%), and no specificity, in detecting tumors ≤2 cm. These observations could be explained by the growth nature of ILC, which has a diffuse, less circumscribed growth pattern without forming any fibrosis, thus complicating identification of ILC margins in the images. [3, 26] Hence, the microCT measured IDC more accurately than ILC. Further, the small number of ILC cases in the study compared to IDC cases may explain the lack of agreement between microCT and pathology measurements of ILC tumor size.
This study had limitations. The first limitation is the small sample size. Since this technology is not a part of standard care, few subjects were enrolled in this study. Additional assessment of microCT using a large sample size is required to validate microCT tumor size measurement. Moreover, further research is required to assess the agreement between microCT and pathology measurements for ILC group.
The second limitation is that the study results can only be generalized to postmenopausal women with an early stage of breast cancer who were treated at the MGH. Because of this, great caution should be considered when interpreting these findings to the general population.
Third, although the definitive tumor size is usually obtained by pathologic measurement, the possibility of variation in tumor size measurement by pathology cannot be excluded because different pathologists performed the tumor size measurement in our study, which could affect the internal validity of these measurements. However, a previous study that was conducted by NHS breast cancer screening program to assess the performance of pathologists by circulating standardized breast cancer slides found that >90% agreement between pathologists in measuring tumor size.
[27]
Finally, because of the small sample size, we were unable to evaluate the effect of the breast cancer grade and presence and percentage of carcinoma in situ components (ductal carcinoma in situ and lobular carcinoma in situ) in measuring and staging tumor size. These factors could have contributed to errors in microCT measurement toward the overestimation of tumor size using microCT measurement.
Even with these limitations, this study had strengths. First, the microCT measurements were performed by an independent physician who received appropriate training in reading the microCT images and measuring the tumor size. In addition, the physician was blinded to the pathology reports and medical records of the subjects. The microCT machine was also calibrated before scanning each lumpectomy specimen, limiting a measurement bias.
Second, because this was a pilot study, it will help to determine the appropriate sample size to assess the microCT breast tumor measurement for a larger study, in order to obtain meaningful results. Moreover, we were able to identify the study limitations that can be addressed in the larger study.
CONCLUSIONS
In our small study, although the microCT tends to yield a slightly larger measurement of breast malignant tumor than the pathological measurement, microCT shows statistically significant strong agreement with histopathological examination in measuring and staging the breast malignant tumors for IDCs. No agreement was found between microCT and pathological measurement for ILC. Further investigation is required to evaluate the microCT in measuring the ILC. Table 1 Table 2 Comparison of tumor size measurement between MicroCT and pathology Table 3 Comparison of Tstage classification between MicroCT and pathology Table 4 Kappa statistics for invasive tumor size and stage group in IDC, and ILC
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BlandAltman plot illustrating the size difference between the microcomputed tomography and pathology against the size average of microcomputed tomography and pathology for invasive ductal carcinoma group Figure 3 
